Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Investment analysts at Alliance Global Partners dropped their Q3 2025 earnings estimates for Curaleaf in a report released on Thursday, August 7th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings of ($0.07) per share for the quarter, down from their prior forecast of ($0.06). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Alliance Global Partners also issued estimates for Curaleaf's FY2025 earnings at ($0.29) EPS.
Separately, Cormark raised shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a research report on Friday.
Read Our Latest Stock Report on Curaleaf
Curaleaf Trading Up 14.0%
Shares of CURLF stock opened at $2.04 on Monday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -6.38 and a beta of 0.69. The company has a quick ratio of 0.70, a current ratio of 1.41 and a debt-to-equity ratio of 1.08. Curaleaf has a fifty-two week low of $0.68 and a fifty-two week high of $3.58. The firm's 50 day moving average price is $1.07 and its two-hundred day moving average price is $1.05.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.41%.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.